deferoxamine has been researched along with Cardiomegaly in 10 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effects of the iron chelator deferoxamine on the functional and structural manifestations of iron-induced cardiac dysfunction, we measured cardiac power, left ventricular systolic, and diastolic function as (dP/dt)max and (dP/dt)min, respectively, and left ventricular and septal wall thickness in isolated heart preparations derived from the Mongolian gerbil model of iron overload." | 7.72 | Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. ( Brittenham, GM; Brown, AM; Dong, WQ; Kuryshev, YA; Levy, MN; Obejero-Paz, CA; Yang, T, 2003) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 5.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| "To evaluate the effects of the iron chelator deferoxamine on the functional and structural manifestations of iron-induced cardiac dysfunction, we measured cardiac power, left ventricular systolic, and diastolic function as (dP/dt)max and (dP/dt)min, respectively, and left ventricular and septal wall thickness in isolated heart preparations derived from the Mongolian gerbil model of iron overload." | 3.72 | Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. ( Brittenham, GM; Brown, AM; Dong, WQ; Kuryshev, YA; Levy, MN; Obejero-Paz, CA; Yang, T, 2003) |
| "Deferoxamine treated control myocytes responded similarly." | 1.36 | Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes. ( Scholz, PM; Tan, T; Weiss, HR, 2010) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 1.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| "Deferoxamine (50 mumol/kg) was given to one group with the hypertrophied hearts during the first 10 minutes of reperfusion." | 1.28 | Deferoxamine fails to improve postischemic cardiac function in hypertrophied hearts. ( del Nido, PJ; Feinberg, H; Jimenez, E; Levitsky, S; Nakamura, H; Sarin, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choy, MK | 1 |
| Movassagh, M | 1 |
| Bennett, MR | 1 |
| Foo, RS | 1 |
| Tan, T | 1 |
| Scholz, PM | 1 |
| Weiss, HR | 1 |
| Yang, T | 1 |
| Brittenham, GM | 1 |
| Dong, WQ | 1 |
| Levy, MN | 1 |
| Obejero-Paz, CA | 1 |
| Kuryshev, YA | 1 |
| Brown, AM | 1 |
| Huang, YC | 1 |
| Chang, JS | 1 |
| Wu, KH | 1 |
| Peng, CT | 1 |
| Hehlmann, R | 1 |
| Schmitz, H | 1 |
| Krüger, K | 1 |
| Engle, MA | 1 |
| Ehlers, KH | 1 |
| O'Loughlin, JE | 1 |
| Giardina, PJ | 1 |
| Hilgartner, MW | 1 |
| Fields, M | 1 |
| Lewis, CG | 1 |
| Lure, M | 1 |
| Nakamura, H | 1 |
| del Nido, PJ | 1 |
| Jimenez, E | 1 |
| Sarin, M | 1 |
| Levitsky, S | 1 |
| Feinberg, H | 1 |
| Silvestroni, E | 1 |
| Bianco, I | 1 |
| Masi, M | 1 |
| Seshadri, R | 1 |
| Colebatch, JH | 1 |
| Gordon, P | 1 |
| Ekert, H | 1 |
10 other studies available for deferoxamine and Cardiomegaly
| Article | Year |
|---|---|
PKB/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2.
Topics: Animals; Cardiomegaly; Cell Line; Cell Size; Chromones; Deferoxamine; Disease Models, Animal; Fibrob | 2010 |
Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes.
Topics: Animals; Carbazoles; Cardiomegaly; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Deferoxamine; D | 2010 |
Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Deferoxamine; Female; Gerbillinae; Heart Failure; Iron; Iro | 2003 |
Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomegaly; Cardiomyopathies; Chelation Therapy; Cohort Studi | 2006 |
Iron overload in cardiac valvular disease and pure red cell aplasia: treatment with desferrioxamine.
Topics: Anemia, Aplastic; Atrial Fibrillation; Cardiomegaly; Deferoxamine; Female; Hemosiderosis; Humans; Ir | 1984 |
Beta thalassemia and heart disease: three decades of gradual progress.
Topics: Blood Transfusion; Cardiomegaly; Child; Deferoxamine; Erythrocyte Transfusion; Heart Diseases; Human | 1985 |
The influence of dietary carbohydrate and deferoxamine on developing copper deficiency of rats.
Topics: Animals; Cardiomegaly; Copper; Deferoxamine; Dietary Carbohydrates; Hematocrit; Male; Rats; Rats, In | 1992 |
Deferoxamine fails to improve postischemic cardiac function in hypertrophied hearts.
Topics: Animals; Cardiomegaly; Deferoxamine; Free Radical Scavengers; Myocardial Reperfusion; Myocardial Rep | 1990 |
[Research on the effect of desferrioxamine B in patients with Cooley's disease].
Topics: Adolescent; Adult; Cardiomegaly; Child; Child, Preschool; Deferoxamine; Female; Hepatomegaly; Humans | 1967 |
Long-term administration of desferrioxamine in thalassaemia major.
Topics: Adolescent; Adult; Aspartate Aminotransferases; Bilirubin; Blood Protein Electrophoresis; Blood Tran | 1974 |